Telix Pharmaceuticals Limited agreed on September 21 to acquire ITM Isotope Technologies Munich SE for up to $2.35 billion. The transaction secures a direct supply of radioactive isotopes for cancer treatments and adds a late-stage drug candidate to Telix's portfolio, though the deal requires shareholder and regulatory approval to close.
The acquisition price consists of $1.65 billion in upfront payment, before cash and debt, plus a further $700 million in milestones. These milestones are contingent on ITM's lead drug winning approval and meeting sales targets. Telix is funding the upfront portion largely through equity, issuing 105.8 million new shares. The remainder of the cost includes assumed ITM debt, transaction fees, and rolled-over management equity. The company expects the deal to close by the end of the year, pending approval from Telix shareholders and relevant regulators.
The strategic rationale centers on the short half-life of radiopharmaceuticals. These drugs treat cancer by delivering radiation directly to tumors, but the radioactive isotopes decay within days. ITM produces lutetium-177, a critical isotope for the field. Telix states that ITM is also the primary outside supplier of this isotope to Pluvicto, a Novartis drug that competes with Telix's own pipeline. By internalizing production, Telix aims to eliminate supplier margins and scheduling risks that could ruin doses if shipments are delayed.
The deal also includes ITM-11, a drug that extended progression-free survival to 23.9 months in gastroenteropancreatic neuroendocrine tumors during trials. However, the U.S. Food and Drug Administration rejected ITM-11 in a complete response letter issued on August 7. Telix describes the issues as related to manufacturing and third-party facility inspections rather than safety or efficacy. The $700 million in milestones will not be triggered until regulators accept the manufacturing fixes.
The immediate market reaction reflected the cost of the equity issuance. Telix shares fell approximately 10% in New York on the announcement day, with a larger drop in Sydney before recovering some ground the following day. The dilution from the 105.8 million new shares presents an immediate cost to existing holders, making the upcoming shareholder vote a critical hurdle. Regulators will also scrutinize Telix's ownership of a key supplier to a competitor.
Telix maintains full-year guidance of $950 million to $970 million while absorbing the manufacturer. According to Insider Monkey data, four hedge funds held a combined stake value of about $3 million in Telix at the end of Q2 2026, an increase from two funds holding around $5.5 million in the previous quarter.